In a recent study published in The New England Journal of Medicine, researchers evaluate the efficacy of plazosiran treatment on fasting triglyceride levels in adult patients with mixed hyperlipidemia ...
PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced results from the Phase 2b double blind, randomized MUIR study of investigational plozasiran (formerly ...
JUPITER 17,802 Rosuvastatin Black: 2224 (12.4%); Hispanic: 2261 (12.7%); other/unknown: 634 (3.6%) 4S: Scandinavian Simvastatin Survival Study; AFCAPS/TEXCAPS: Air Force/Texas Coronary Atherosclerosis ...
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive topline results from the first two of three Phase 3 clinical trials ...
In a breakthrough for cardiovascular medicine, researchers have harnessed artificial intelligence to discover unexpected lipid-lowering effects in existing FDA-approved drugs. The study, published in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback